{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Abbreviation', 'Definition', 'IEC', 'Independent Ethics Committee', 'IL-36', 'Interleukin-36', 'IL-36R', 'Interleukin-36 receptor', 'IRB', 'Institutional Review Board', 'IV', 'Intravenous', 'JDA', 'Japanese Dermatology Association', 'mAb', 'Monoclonal antibody', 'MAD', 'Multiple Ascending Dose', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'mRNA', 'Messenger ribonucleic acid', 'NaCl', 'Sodium chloride', 'PASI', 'Psoriasis Area Severity Index', 'PK', 'Pharmacokinetic', 'PP', 'Plaque psoriasis', 'PPP', 'Palmoplantar pustular psoriasis', 'PT', 'Preferred term', 'PUVA', 'Psoralen and Ultraviolet A', 'QoL', 'Quality of life', 'RNA', 'Ribonucleic acid', 'SAD', 'Single Ascending Dose', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SC', 'Subcutaneous', 'SD', 'Standard deviation', 'SOC', 'System Organ Class', 'SOP', 'Standard operating procedures', 'TB', 'Tuberculosis', 'TEAE', 'Treatment-emergent adverse event', 'Tmax', 'Time to maximum observed concentration', 'ULN', 'Upper limit of normal', 'URTI', 'Upper respiratory tract infection', 'WBC', 'White blood cell', 'WOCBP', 'Women of childbearing potential', '29 October 2019', '59']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Appendix 2', 'Regulatory, Ethical, and Study Oversight Considerations', 'Regulatory and Ethical Considerations', 'This study will be conducted in accordance with the protocol and with the following:', '- Consensus ethical principles derived from international guidelines including the', 'Declaration of Helsinki and Council for International Organizations of Medical', 'Sciences (CIOMS) International Ethical Guidelines.', '- Applicable International Council for Harmonisation (ICH) GCP Guidelines.', '- Applicable laws and regulations.', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant', 'documents (eg, advertisements) must be submitted to an IRB/IEC by the Investigator and', 'reviewed and approved by the IRB/IEC before the study is initiated.', 'Any amendments to the protocol will require IRB/IEC and regulatory authority approval,', 'when applicable, before implementation of changes made to the study design, except for', 'changes necessary to eliminate an immediate hazard to subjects.', 'The Investigator will be responsible for the following:', '- Providing written summaries of the status of the study to the IRB/IEC annually or', 'more frequently in accordance with the requirements, policies, and procedures', 'established by the IRB/IEC.', '- Notifying the IRB/IEC of SAEs or other significant safety findings as required by', 'IRB/IEC procedures.', '- Providing oversight of the conduct of the study at the study center and adherence to', 'requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014', 'for clinical studies (if applicable), and all other applicable local regulations.', 'After reading the protocol, each Investigator will sign the protocol signature page and send a', 'copy of the signed page to the Sponsor or representative. The study will not start at any study', 'center at which the Investigator has not signed the protocol.', 'Insurance', 'Sponsor will provide insurance in accordance with local guidelines and requirements as', 'minimum for the subjects in this study. The terms of the insurance will be kept in the study files.', 'Informed Consent Process', 'The Investigator or his/her representative will explain the nature of the study to the subject or', 'his/her legally authorized representative and answer all questions regarding the study.', 'Subjects must be informed that their participation is voluntary. Subjects or their legally', 'authorized representative will be required to sign a statement of informed consent that meets', 'the requirements of 21 CFR 50, local regulations, ICH guidelines, Health Insurance', '29 October 2019', '60']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'Portability and Accountability Act requirements, where applicable, and the IRB/IEC or study', 'center.', 'The medical record must include a statement that written informed consent was obtained', 'before the subject was entered in the study and the date the written consent was obtained.', 'The authorized person obtaining the informed consent must also sign the ICF.', 'Subjects must be re-consented to the most current version of the ICF(s) during their', 'participation in the study.', \"A copy of the ICF(s) must be provided to the subject or the subject's legally authorized\", 'representative.', 'Subjects who are rescreened are required to sign a new ICF.', 'The ICF will contain a separate section that addresses the use of remaining mandatory samples', 'for optional exploratory research. The Investigator or authorized designee will explain to each', 'subject the objectives of the exploratory research. Subjects will be told that they are free to', 'refuse to participate and may withdraw their consent at any time and for any reason during the', \"storage period. A separate signature will be required to document a subject's agreement to allow\", 'any remaining specimens to be used for exploratory research. Subjects who decline to participate', 'in this optional research will not provide this separate signature.', 'Data Protection', 'Subjects will be assigned a unique identifier by the Sponsor. Any subject records or datasets', 'that are transferred to the Sponsor will contain the identifier only; subject names or any', 'information which would make the subject identifiable will not be transferred.', 'The subject must be informed that his/her personal study related data will be used by the', 'Sponsor in accordance with local data protection law. The level of disclosure must also be', 'explained to the subject.', 'The subject must be informed that his/her medical records may be examined by Clinical', 'Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by', 'appropriate IRB/IEC members, and by inspectors from regulatory authorities.', 'The ICF will incorporate (or, in some cases, be accompanied by a separate document', 'incorporating) wording that complies with relevant data protection and privacy legislation.', 'The Sponsor or its representative will not provide individual genotype results to subjects, any', 'insurance company, any employer, their family members, general physician, or any other', 'third party, unless required to do so by law.', 'Extra precautions are taken to preserve confidentiality and prevent genetic data being linked', 'to the identity of the subject. In exceptional circumstances, however, certain individuals', 'might see both the genetic data and the personal identifiers of a subject. For example, in the', 'case of a medical emergency, the Sponsor or representative physician or an Investigator', \"might know a subject's identity and also have access to his or her genetic data. Also\", 'regulatory authorities may require access to the relevant files.', '29 October 2019', '61']\n\n###\n\n", "completion": "END"}